Transcatheter tricuspid valve repair and replacement

Series
Cardiovascular
Status
Published
Date
Number of report
09

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for minimally invasive tricuspid valve repair and replacement procedures. The procedures performed via endovascular and transapical approach are considered.

Reimbursement analysis will cover the following procedures:

  • transcatheter tricuspid valve repair;
  • transcatheter tricuspid valve replacement.

The diagnosis of nonrheumatic tricuspid (valve) insufficiency is considered as an indication for procedures.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

Table of content is not available at the moment. Report is still ongoing.

09

Dec 2021

In November 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous implantation of pulmonary artery pressure sensors in chronic heart failure and coronary sinus narrowing device implantation for refractory angina), one new Medical Technologies Guidance (Synergo for non-muscle-invasive bladder cancer), one new Diagnostic Guidance (SeHCAT for diagnosing bile acid diarrhea), and four new Medtech Innovation Briefings (clonoSEQ for minimal residual disease, CerebAir for continuous EEG monitoring, 24/7 EEG SubQ for epilepsy, Paige Prostate for prostate cancer). Also, three new clinical guidelines were published, and six were updated.

Read more
(we accept only company emails)